Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than cash value -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (582)	8/6/2021 7:09:31 PM
From: A.J. Mullen	2 Recommendations Recommended By Lance Bredvold scaram(o)uche Read Replies (1) \| Respond to of 684

I gave FGEN the benefit of the doubt when they announced the post-hoc stratification although if a mistake, it was an embarrassingly basic one. They were suave pressing for approval, proposing a bunch of ad hoc changes as responses to inadequacies demonstrated by the trials. That was brazen. They have approval and sales in China and Japan, and the EU seemed headed that way until the FDA meeting. The Europeans and Japanese might think again now. If China has insufficient machines to provide daily dialysis for all in need, the risk calculation will likely be different. Ashley